Taking advantage of a recent high in the company's stock price, Isis Pharmaceuticals offered up to 10.4 million shares of common stock at $19 each for net proceeds of $186.4 million.
The stock sale priced just one day after a first quarter 2013 earnings report that showed $371.9 million in cash...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?